Rev Esp Quimioter 2021; 34(2): 136-140

Real-life use of remdesivir in hospitalized patients with COVID-19

CAROLINA GARCIA-VIDAL, FERNANDA MEIRA, ALBERTO CÓZAR-LLISTÓ, GERARD DUEÑAS, PEDRO PUERTA-ALCALDE, NICOLE GARCIA-POUTON, MARIANA CHUMBITA, CELIA CARDOZO, MARTA HERNANDEZ-MENESES, RODRIGO ALONSO-NAVARRO, VERÓNICA RICO, DAIANA AGÜERO, MARTA BODRO, LAURA MORATA, CARLOTA JORDAN, CARLOS LOPERA, JUAN AMBROSIONI, FERRAN SEGUI, NACHO GRAFIA, PEDRO CASTRO, FELIPE GARCÍA, JOSEP MENSA, JOSÉ ANTONIO MARTÍNEZ, GEMMA SANJUAN, ALEX SORIANO, AND COVID19-RESEARCHER GROUP

Published: 6 March 2021

http://www.doi.org/10.37201/req/018.2021

Objective. Controversial results on remdesivir efficacy have been reported. We aimed to report our real-life experience with the use of remdesivir from its availability in Spain.
Methods. We performed a descriptive study of all patients admitted for ≥48 hours with confirmed COVID-19 who received remdesivir between the 1st of July and the 30th of September 2020.
Results. A total of 123 patients out of 242 admitted with COVID-19 at our hospital (50.8%) received remdesivir. Median age was 58 years, 61% were males and 56.9 % received at least one anti-inflammatory treatment. No adverse events requiring remdesivir discontinuation were reported. The need of intensive care unit admission, mechanical ventilation and 30-days mortality were 19.5%, 7.3% and 4.1%, respectively.
Conclusion. In our real-life experience, the use of remdesivir in hospitalized patients with COVID-19 was associated with a low mortality rate and good safety profile.

Rev Esp Quimioter 2021; 34(2): 136-140 [Full-text PDF]